Abstract 170P
Background
The aim of the present study was to perform a real-world analysis on a large sample of patients with intermediate BCLC-B patients with HCC treated with A+B vs Lenvatinib.
Methods
The study population included patients enrolled affected by intermediate (BCLC-B) HCC patients not suitable for locoregional therapies from eastern and western populations, who received A+B or Lenvatinib as first-line treatment. Univariate and multivariate analyses were used to evaluate predictor factors for overall survivor (OS) and progression free survivor (PFS) while prognostic factors were analyzed by univariate and multivariate analysis using Cox regression model.
Results
919 BCLC-B HCC patients were enrolled in the study: 561 (61%) received Lenvatinib and 358 (39%) received A+B. The mOS for patients receiving Lenvatinib was 21,3 months compared to 15,8 months for patients receiving A+B as first-line treatment (Lenvatinib Vs A+B): HR 0,84 p =0,22. The mPFS for patients receiving Lenvatinib was 7,34 months compared to 8,68 months for patients receiving A+B as first-line treatment (Lenvatinib vs A+B): HR 1,15 p = 0,10. The multivariate analysis confirmed no different in terms of mOS and mPFS between the two treatments. Objective response rate (ORR) was 47,11 % for patients receiving Lenvatinib and 27 % for patients receiving A+B p < 0, 000001. Patients receiving Lenvatinib experienced a significantly higher incidence of hand-foot skin reaction (HFSR), hypertension, diarrhea, fatigue, decrease appetite, hypothyroidism, and other toxicity compared to patients receiving A+B. Favorable prognostic factors for OS in Lenvatinib group was platelets >100, HR 0,68 p= 0,02. No favorable prognostic factors were found for A+B group. Favorable prognostic factors for pfs in the A+B group were in those who performed at least one TACE previously HR 0.76 p=0.02, platelets <100 HR 0.62 p=0.0067, and nlr <3 HR 0.78 p=0.04.
Conclusions
Although Lenvatinib had a greater response, the study showed no statistically significant differences between Lenvatinib and A+B in terms of efficacy, in these two cohorts of BCLC-B HCC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract